AU2007349237B2 - Potent and selective mediators of cholesterol efflux - Google Patents

Potent and selective mediators of cholesterol efflux Download PDF

Info

Publication number
AU2007349237B2
AU2007349237B2 AU2007349237A AU2007349237A AU2007349237B2 AU 2007349237 B2 AU2007349237 B2 AU 2007349237B2 AU 2007349237 A AU2007349237 A AU 2007349237A AU 2007349237 A AU2007349237 A AU 2007349237A AU 2007349237 B2 AU2007349237 B2 AU 2007349237B2
Authority
AU
Australia
Prior art keywords
polypeptide
polypeptides
seq
amino acids
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007349237A
Other languages
English (en)
Other versions
AU2007349237A1 (en
Inventor
John K. Bielicki
Jan Johansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2007349237A1 publication Critical patent/AU2007349237A1/en
Application granted granted Critical
Publication of AU2007349237B2 publication Critical patent/AU2007349237B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007349237A 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux Ceased AU2007349237B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
US60/874,909 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (2)

Publication Number Publication Date
AU2007349237A1 AU2007349237A1 (en) 2008-09-25
AU2007349237B2 true AU2007349237B2 (en) 2014-01-23

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007349237A Ceased AU2007349237B2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Country Status (10)

Country Link
US (1) US8987192B2 (enExample)
EP (1) EP2121746B1 (enExample)
JP (1) JP2010513311A (enExample)
CN (1) CN101675072A (enExample)
AT (1) ATE533783T1 (enExample)
AU (1) AU2007349237B2 (enExample)
CA (1) CA2672131C (enExample)
DK (1) DK2121746T3 (enExample)
ES (1) ES2377329T3 (enExample)
WO (1) WO2008115303A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011101536A (ru) 2008-06-18 2012-07-27 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа (Us) Усовершенствованные пептидные медиаторы оттока холестерина
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
WO2011139819A2 (en) * 2010-04-28 2011-11-10 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
US11091529B2 (en) * 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020040A2 (en) * 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
CA2405870A1 (en) * 2000-04-06 2001-10-18 Kos Pharmaceuticals, Inc. Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7691965B2 (en) 2002-05-08 2010-04-06 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020040A2 (en) * 2004-07-16 2006-02-23 Trustees Of Tufts College Apolipoprotein a1 mimetics and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ramprasad, M. P. et al (2002) J. Contr. Release, 79:207-218 *

Also Published As

Publication number Publication date
EP2121746A2 (en) 2009-11-25
ES2377329T3 (es) 2012-03-26
CA2672131C (en) 2016-06-07
ATE533783T1 (de) 2011-12-15
HK1138292A1 (en) 2010-08-20
WO2008115303A2 (en) 2008-09-25
WO2008115303A3 (en) 2008-12-24
CA2672131A1 (en) 2008-09-25
US8987192B2 (en) 2015-03-24
US20120329703A1 (en) 2012-12-27
EP2121746B1 (en) 2011-11-16
DK2121746T3 (da) 2012-03-05
CN101675072A (zh) 2010-03-17
JP2010513311A (ja) 2010-04-30
AU2007349237A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
US8415293B2 (en) Peptide mediators of cholesterol efflux
US11434267B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
AU2007349237B2 (en) Potent and selective mediators of cholesterol efflux
AU2004299486B2 (en) Helical synthetic peptides that stimulate cellular cholesterol efflux
US20130123173A1 (en) Creation of oxidation-resistant hdl mimetic peptides
HK1138292B (en) Potent and selective mediators of cholesterol efflux
US11091529B2 (en) Peptides having reduced toxicity that stimulate cholesterol efflux

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired